

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Carmustine implants for the treatment of recurrent glioblastoma multiforme

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Link Pharmaceuticals (carmustine implants) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Brain Tumour UK • British Brain and Spine Foundation • British Brain Tumour Association • Cancer Black Care • Cancer Voices • Cancerbackup • National Cancer Alliance • National Council for Palliative Care • Neurological Alliance • Samantha Dickson Research Trust • Specialised Healthcare Alliance • Tenovus Cancer Information Centre <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Association of Surgical Oncology • British Oncological Association • British Psychosocial Oncology Society • Cancer Networks Pharmacists Forum • Cancer Research UK • Institute of Neurology, UCL • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians' Medical Oncology Joint Special Committee 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • Cancer Care Cymru • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency (MHRA) • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supplies Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufactures</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb Pharmaceuticals Ltd (carmustine) • Cambridge Laboratories (procarbazine) • Clonmel Healthcare Ltd (vincristine) • Mayne Pharma plc (vincristine) • Medac UK (lomustine) • Schering-Plough Ltd (temozolomide) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Centre for Reviews and Dissemination, University of York and Centre for Health Economics, University of York • National Coordinating Centre for Health Technology Assessment

National Institute for Health and Clinical Excellence
Appraisal of Carmustine implants for the treatment of recurrent glioblastoma multiforme

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Radiologists • Royal College of Surgeons • Royal Society of Medicine – Intellectual Disabilities Forum • Society of British Neurological Surgeons <p><u>Others</u></p> <ul style="list-style-type: none"> • Hastings and Rother PCT • Department of Health • Welsh Assembly Government 	<p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer

Definitions:Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient

National Institute for Health and Clinical Excellence
Appraisal of Carmustine implants for the treatment of recurrent glioblastoma multiforme

Issue date: May 2007

organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.